SCHEMBL61372

SCHEMBL61372

NC(=O)[C@H](N)CC[C]=O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5557115 1.00
SCHEMBL169475 1.00
SCHEMBL157042 0.80
SCHEMBL639292 0.80
SCHEMBL157041 0.80
SCHEMBL14956926 0.78 ALOX15 (0.43)
SCHEMBL17541311 0.78 ALOX15 (0.43)
SCHEMBL15676365 0.78 ALOX15 (0.43)
SCHEMBL20924801 0.74 ALOX15 (0.37)
SCHEMBL7398604 0.74

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0615522-B1 MURAMYL COMPOUNDS FOR TREATMENT OF SEPTIC SHOCK PEPTECH UK LTD (GB) 1999-09-22 EP claimed
EP-0722332-B1 TREATMENT OF PRECANCEROUS LESIONS BY MURAMYL PEPTIDES PEPTECH UK LTD (GB) 1999-08-18 EP claimed
US-5877147-A MURAMYL PEPTIDE FOR PROPHYLAXIS OF CANCER PEPTECH (UK) LIMITED (GB) 1999-03-02 US claimed
US-5534492-A Muramyl peptide for the treatment of toxicity PEPTECH (UK) LIMITED (GB) 1996-07-09 US claimed
EP-0615522-A1 MURAMYL COMPOUNDS FOR TREATMENT OF SEPTIC SHOCK PEPTECH (UK) LIMITED (GB) 1994-09-21 EP claimed
WO-1993016713-A2 USE OF MURAMYL PEPTIDE FOR THE TREATMENT OF TOXICITY PEPTECH (UK) LIMITED (GB) 1993-09-02 WO claimed
WO-1993013791-A1 USE OF MURAMYL PEPTIDES FOR ENHANCING ANIMAL PRODUCTION PEPTECH (UK) LIMITED (GB) 1993-07-22 WO claimed
WO-1993010148-A1 MURAMYL COMPOUNDS FOR TREATMENT OF SEPTIC SHOCK PEPTECH (UK) LIMITED (GB) 1993-05-27 WO claimed
EP-0157753-B1 NEW SOMATOSTATIN COMPOUNDS, PROCESS FOR THEIR SYNTHESIS, PREPARATION FOR VETERINARY USE CONTAINING SAID COMPOUND AND PROCESS FOR THE TREATMENT OF ANIMALS TECHLAND, Société Anonyme (BE) 1987-11-11 EP claimed
EP-0157753-A1 New somatostatin compounds, process for their synthesis, preparation for veterinary use containing said compound and process for the treatment of animals TECHLAND, Société Anonyme (BE) 1985-10-09 EP claimed
US-20210145975-A1 IMMUNOGENIC COMPOUND ALTIMMUNE UK LTD (GB) 2021-05-20 US disclosed
US-10849984-B2 Immunogenic compound ALTIMMUNE UK LIMITED (GB) 2020-12-01 US disclosed
US-20200038519-A1 IMMUNOGENIC COMPOUND ALTIMMUNE UK LIMITED 2020-02-06 US disclosed
US-10434183-B2 Immunogenic compound Altimmune UK Ltd. (GB) 2019-10-08 US disclosed
US-10342874-B2 Glucosamine peptide compounds for treating liver metabolic disorders FAR EASTERN MEMORIAL HOSPITAL (TW) 2019-07-09 US disclosed
EP-0399843-A2 Adjuvant formulation comprising a submicron oil droplet emulsion CHIRON CORPORATION (US) 1990-11-28 EP disclosed
EP-0157753-B1 NEW SOMATOSTATIN COMPOUNDS, PROCESS FOR THEIR SYNTHESIS, PREPARATION FOR VETERINARY USE CONTAINING SAID COMPOUND AND PROCESS FOR THE TREATMENT OF ANIMALS TECHLAND, Société Anonyme (BE) 1987-11-11 EP disclosed
EP-0157753-A1 New somatostatin compounds, process for their synthesis, preparation for veterinary use containing said compound and process for the treatment of animals TECHLAND, Société Anonyme (BE) 1985-10-09 EP disclosed
US-4461761-A IMMUNO-REGULATORS AGENCE NATIONALE DE VALORISATION DE LA RECHERCHE (ANVAR) (FR) 1984-07-24 US disclosed
US-4461761-A IMMUNO-REGULATORS AGENCE NATIONALE DE VALORISATION DE LA RECHERCHE (ANVAR) (FR) 1984-07-24 US disclosed